Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer

被引：0
|
作者：
Andreas Teufel
Silke Steinmann
Jürgen Siebler
Christiane Zanke
Herbert Hohl
Bernd Adami
M Schroeder
O Klein
Thomas Höhler
Peter R Galle
Michael Heike
Markus Moehler
机构：
[1] Johannes Gutenberg University,Dept. of Internal Medicine I, Outpatient Unit for GI Cancer
[2] Hospital Bad Ems,undefined
[3] Outpatient Unit,undefined
[4] General practice,undefined
[5] General practice,undefined
[6] General practice,undefined
来源：
BMC Cancer | / 4卷
关键词：
irinotecan; 5-fluorouracil; safety; metastatic colorectal cancer; neoadjuvant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer.: EORTC study 40015
    Koehne, C.-H.
    De Greve, J.
    Hartmann, J. T.
    Lang, I.
    Vergauwe, P.
    Becker, K.
    Braumann, D.
    Joosens, E.
    Mueller, L.
    Janssens, J.
    Bokemeyer, C.
    Reimer, P.
    Link, H.
    Spath-Schwalbe, E.
    Wilke, H. -J.
    Bleiberg, H.
    Van den Brande, J.
    Debois, M.
    Bethe, U.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2008, 19 (05) : 920 - 926
  • [32] Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer
    Xie, Song
    Han, Guoping
    Fan, Zhikun
    He, Lifeng
    Xu, Wenbing
    Qin, Zhen
    MEDICAL ONCOLOGY, 2014, 31 (07)
  • [33] Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)
    Maindrault-Goebel, F
    Louvet, C
    André, T
    Carola, E
    Lotz, JP
    Molitor, JL
    Garcia, ML
    Gilles-Amar, V
    Izrael, V
    Krulik, M
    de Gramont, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (09) : 1338 - 1342
  • [34] Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer
    Song Xie
    Guoping Han
    Zhikun Fan
    Lifeng He
    Wenbing Xu
    Zhen Qin
    Medical Oncology, 2014, 31
  • [35] Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer
    Rocha, Jose Aurillo
    ANTI-CANCER DRUGS, 2011, 22 : S9 - S13
  • [36] Irinotecan versus infusional 5-fluorouracil: A phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil
    Van Cutsem, E
    Blijham, GH
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 13 - 20
  • [37] Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial
    Souglakos, J
    Pallis, A
    Kakolyris, S
    Mavroudis, D
    Androulakis, N
    Kouroussis, C
    Agelaki, S
    Xenidis, N
    Milaki, G
    Georgoulias, V
    ONCOLOGY, 2005, 69 (05) : 384 - 390
  • [38] CYTARABINE AND CISPLATIN AS SALVAGE THERAPY IN PATIENTS WITH METASTATIC COLORECTAL-CANCER WHO FAILED 5-FLUOROURACIL PLUS FOLINIC ACID REGIMEN
    ADENIS, A
    CARLIER, D
    DARLOY, F
    PION, JM
    BONNETERRE, J
    DEMAILLE, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (02): : 158 - 160
  • [39] Bimonthly Chemotherapy with Oxaliplatin, Irinotecan, Infusional 5-Fluorouracil/Folinic Acid in Patients with Metastatic Colorectal Cancer Pretreated with Irinotecan- or Oxaliplatin-Based Chemotherapy
    Nobili, S.
    Checcacci, D.
    Filippelli, F.
    Del Buono, S.
    Mazzocchi, V.
    Mazzei, T.
    Mini, E.
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (05) : 622 - 631
  • [40] Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer
    Moehler, M
    Hoffmann, T
    Zanke, C
    Hohl, H
    Burg, H
    Ehscheid, P
    Schwindt, P
    Adami, B
    Schroeder, M
    Klein, O
    Baldus, M
    Galle, PR
    Heike, M
    ANTI-CANCER DRUGS, 2003, 14 (01) : 79 - 85
12345